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ORIGINAL ARTICLE
The effect of asparaginase therapy on methotrexate toxicity and efficacy in
children with acute lymphoblastic leukemia
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and Inge M. van der Sluisa,b
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bPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands; cAcademic Medical Center, Amsterdam, The Netherlands;
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ABSTRACT
Asparaginase and methotrexate (MTX), both essential for pediatric acute lymphoblastic leukemia
therapy, are often used concomitantly. Depending on the sequence, in vitro, asparaginase inhib-
its MTX-polyglutamate (MTXPG) formation, and side effects overlap. MTX toxicity and efficacy,
reflected by intracellular erythrocyte MTXPG’s, were compared between children treated with
and without asparaginase during high dose MTX (HD-MTX) courses of the DCOG ALL-11 proto-
col (NL50250.078.14). Seventy-three patients, of whom 23 received asparaginase during the HD-
MTX courses, were included. Grade 3–4 leukopenia and neutropenia occurred more often (59%
and 86% vs. 30% and 62%). The number of infections, grade 3–4 hepatotoxicity, nephrotoxicity,
and neurotoxicity did not differ. Patients with asparaginase had lower MTXPG levels, although
to a lesser extent than in vitro studies. Although patients with asparaginase during HD-MTX
courses showed more myelosuppression, this had no (serious) clinical consequences. Regarding
the MTX efficacy, the schedule-related antagonism seen in in vitro seems less important in vivo.
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Introduction
Asparaginase and methotrexate (MTX) are both essential
for the treatment of pediatric acute lymphoblastic leuke-
mia (ALL). These drugs are often used concomitantly,
among other chemotherapeutics, to achieve better sur-
vival rates [1–8]. The sequence of administration, how-
ever, seems important as several in vitro studies have
shown an antagonistic effect of native Escherichia coli
asparaginase on MTX when asparaginase is administered
prior to the MTX [9–12]. It has been shown that MTX
efficacy, reflected by intracellular MTX polyglutamates
(MTXPGs) [13–15], is decreased due to the asparagine
depletion caused by asparaginase. The asparagine deple-
tion inhibits folylpolyglutamyl synthetase (FPGS), the
enzyme that forms the MTXPGs [10,12,16–18]. In con-
trast, if asparaginase is administered after MTX, there
seems to be a synergistic effect in vitro [12]. Moreover,
in vivo, MTX is administered prior to native E. coli aspara-
ginase with the Capizzi regimen, increasing the dose
guided by toxicity, which permits toleration of higher
MTX doses and leads to successful remission rates [16].
Currently, most treatment protocols use
PEGasparaginase, with therapeutic activity of at least
two weeks, resulting in continuous asparagine deple-
tion [19]. So treating patients with PEGasparaginase
during MTX doses may influence the formation of
MTXPGs, independently of the sequence of administra-
tion. Treatment protocols using these dosing sched-
ules, however, are successful, suggesting that in vivo
the effect of asparaginase on MTX efficacy seems less
important [6,20,21].
Beside MTX efficacy, concomitant asparaginase and
MTX therapy may alter toxicity profiles because the
drugs have overlapping side effects, including neuro-
toxicity, hepatotoxicity, and myelosuppression. On the
other hand, MTX toxicity can be decreased in vitro by
drugs that prevent cells from entering the S-phase,
which is the case when asparaginase depletes the
extracellular asparagine pools [22].
In the current Dutch Childhood Oncology Group
(DCOG) ALL-11 protocol, medium risk patients are
being randomized either to a continuous or a discon-
tinuous PEGasparaginase dosing schedule, which
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contains an asparaginase-free period of several
months, to study the effect of the dosing schedule on
the occurrence of hypersensitivity reactions. Patients
who are treated according to the continuous dosing
schedule are concomitantly treated with asparaginase
and high dose MTX courses, enabling us to study the
possible effects of asparaginase on MTX efficacy and
toxicity. The aim of this study is to compare the MTX
efficacy, reflected by intracellular erythrocyte MTXPG
levels, and toxicity between patients who are treated
with high dose MTX courses with and without con-
comitant PEGasparaginase treatment.
Methods
Patients and treatment
Pediatric patients with ALL, diagnosed between
November 2014 and June 2017, and treated according
to the medium or standard risk group of the DCOG
ALL-11 protocol were included in this study. The
patients were treated in the Sophia Children’s
Hospital, Rotterdam, The Netherlands; the Academic
Medical Center, Amsterdam, The Netherlands; or the
Princess Maxima Center for Pediatric Oncology,
Utrecht, The Netherlands. The study (CCMO register:
NL50250.078.14) was approved by the local ethics
committee and informed consent was signed by chil-
dren >12 years old and/or the parents or guardians in
accordance with the declaration of Helsinki.
The complete DCOG ALL-11 treatment protocol is
described in Table 1. Both standard and medium risk
patients treated according to the discontinuous aspar-
aginase dosing group, received three doses of
PEGasparaginase (1500 IU/m2, IV, biweekly) during
induction (course 1(A) and 1(B)), followed by an aspar-
aginase-free interval of 12 weeks (remaining course
1(B) and M). During the following intensification
phase, standard risk patients received one more
PEGasparaginase dose; medium risk patients another
14 doses. The medium risk patients who were treated
according to the continuous dosing schedule, received
the PEGasparaginase once every two weeks, also dur-
ing the consecutive courses 1(B) and M. The
PEGasparaginase doses were individualized after the
third dose, based on asparaginase activity levels [23].
The asparaginase-free period for both standard and
medium risk patients of the discontinuous dosing
schedule started with course 1(B) containing 6-mer-
captopurine, cytarabine, and cyclophosphamide, fol-
lowed by course M with four high dose MTX courses
(5000mg/m2/dose IV over 24 h) and 6-mercaptopurine
(25mg/m2/day orally) (Table 1). MTX was administered
biweekly, except if patients suffered from a (severe)
infection, mucositis or hepatotoxicity (AST/ALT >10
upper limit of normal), or when the white blood count
was <1.5 109 or platelets were <50 109. In that
case, the course was postponed for at least one week.
Folinic acid was administered after the MTX dose until
the 48 h plasma MTX level was <0.4 lM or the 72 h
plasma MTX level <0.25lM. The patients with the
continuous asparaginase dosing schedule also
received PEGasparaginase during course 1(B) and M.
The asparaginase doses were administered biweekly,
even if the requirements of MTX administration were
not fulfilled and MTX had to be postponed. This is
also true for any delay in protocol 1(B), for example, if
Table 1. DCOG ALL-11 protocol for medium and standard risk patients.
Treatment phase Therapy
Protocol 1(A)
Prednisone 60mg/m2/day for 29 days followed by 9 days tapering
Vincristine 1.5mg/m2/dose at day 8, 15, 22 and 29
Daunorubicin 30mg/m2/dose at day 8, 15, 22 and 29 (not in case of Down syndrome)
PEGasparaginase 1500 IU/m2 at day 12, 26
Intrathecal MTX, cytarabine,
and prednisone
8–12mg MTX, 20–30mg cytarabine, 8–12mg prednisone at day 15 and 33. Only intrathecal MTX at day 1.
Protocol 1(B)
PEGasparaginasea 1500 IU/m2 at day 40
Cyclophosphamide 1000mg/m2/dose at day 36 and 64
Cytarabine 75mg/m2/day at days 38–41, 45–48, 52–55, 59–62
6-Mercaptopurine 60mg/m2/day at days 36–63
Intrathecal MTX, cytarabine,
and prednisone
8–12mg MTX, 20–30mg cytarabine, 8–12mg prednisone at day 45 and 59
Protocol M
6-Mercaptopurine 25mg/m2/day for 56 days
MTX 5000mg/m2over 24 h, at day 8, 22, 36 and 50
Intrathecal MTX, cytarabine,
and prednisone
8–12mg MTX, 20–30mg cytarabine, 8–12mg prednisone at day 8, 22, 36 and 50
PEGasparaginase Only continuous group: individualized doses, biweekly
MTX: methotrexate.
aMedium risk patients in the continuous dosing schedule will continue PEGasparaginase treatment during course 1(B) and M, administered biweekly.
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cyclophosphamide has to be postponed. Evidently,
patients had to fulfill the requirements for asparagi-
nase administration, which included the absence of
hepatotoxicity (AST/ALT >10 and bilirubin >3
upper limit of normal), jaundice, clinical signs of pan-
creatitis, and cerebral thrombosis.
Toxicity
Methotrexate toxicity was prospectively studied using
case report forms which were completed by the phys-
ician two weeks after each high dose MTX course.
These toxicity forms included central neurotoxicity
(ataxia, somnolence, a depressed level of conscious-
ness, agitation, seizures, and posterior reversible
encephalopathy syndrome), infections, mucositis, and
diarrhea. In addition, complete blood count, liver
enzymes (alanine transaminase (ALT) and aspartate
transaminase (AST)), creatinine and albumin concentra-
tions were measured prior to the next high dose MTX
courses. Toxicity was graded according to the
Common Terminology Criteria for Adverse Events
(CTCAE) version 4.03. In addition, total treatment delay
due to toxicity, extra hospital admissions, and pro-
longation of hospital admissions for MTX administra-
tion were registered.
MTX polyglutamates
MTX polyglutamates were measured two to three
weeks after each MTX course. Blood was drawn to
measure intracellular MTXPG concentrations in the
erythrocytes as described by Den Boer et al. [24] EDTA
whole blood tubes were centrifuged at 2700 g for
10min at room temperature. The red cell pellet was
harvested and stored at 80 C until analysis. For the
analysis, first stable-isotope-labeled internal standards
were added, followed by incubation of the sample
with 16% perchloric acid for protein precipitation.
After centrifugation at 21,350g for 7min, MTXPG
1–5 concentrations were measured using liquid chro-
matography-electrospray ionization-tandem mass
spectrometry (LC-ESI-MS/MS). MTXPG 1 is freely trans-
portable out of the cells, so very variable [25].
Therefore, only MTXPG 2–5 were used for the analysis.
Beside the intracellular MTXPG levels, 48 h plasma
MTX levels were analyzed.
Statistical analysis
SPSS Statistics version 21.0 (IBM Corp, Armonk, New
York, USA) and R Sigmaplot Version 3.4.1 (Systat
Software Inc, London, UK) were used for the data ana-
lysis. Baseline characteristics were stated as mean and
standard deviation (SD) for normally distributed data,
and median and interquartile range (IQR) for skewed
data. Student t-tests, Mann–Whitney U tests, v2-
(trend)tests, Fisher exact tests, and corresponding
post-hoc analyses were used to compare the baseline
characteristics and maximal toxicity during protocol M.
The MTXPG levels were longitudinally analyzed using
marginal models to study the levels between patients
with and without concomitant asparaginase treatment.
The data were log transformed to obtain normally dis-
tributed data. We have corrected for the number of
days between the MTX dose and sampling, the MTX
dose number, age, sex, and whether there was an
erythrocyte transfusion administered less than two
weeks before the sample. In addition, we have studied
whether asparaginase doses were administered dir-
ectly after the MTX doses or one week after the MTX
dose. The 48 h MTX plasma levels were also analyzed
with marginal models. The data were log transformed
to obtain normally distributed data. In the model, we
have corrected for sex, age, the MTX dose number,
albumin levels and whether patients had an increased
creatinine level. Also in this analysis, it was included
whether asparaginase doses were administered dir-
ectly after the MTX doses or one week after the
MTX dose.
Results
Baseline characteristics are described in Table 2. In
total, 73 patients were included in the study. Twenty-
three patients were concomitantly treated with aspara-
ginase during the high dose MTX courses in protocol
M. Of the group without asparaginase treatment dur-
ing the MTX courses, 17/50 (34%) were treated accord-
ing to the standard risk group; the other 33 patients
according to the discontinuous dosing schedule of the
medium risk group. Of the group with concomitant
asparaginase treatment, one patient had to switch to
the high-risk group halfway during protocol M due to
high minimal residual disease.
There were no statistically significant differences in
other baseline characteristics between the patients
with and without asparaginase treatment during
protocol M. Of note, some of the patients were stand-
ardly treated with intravenous immunoglobulins (IVIG)
as part of another randomized study. The number of
patients standardly treated with IVIG, however, did not
differ between the groups.
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Toxicity
The maximum toxicity per group and the number of
infections and transfusions during protocol M are
described in Table 3. Patients with asparaginase treatment
during the high dose MTX courses received significantly
more erythrocyte and thrombocyte transfusions (median
and IQR of 1 (0.75–2) and 0 (0–0.25), respectively) than
patients without concomitant asparaginase treatment
(median and IQR of 0 (0–0) and 0 (0–0), respectively).
Patients with asparaginase treatment received a
maximum of 5 erythrocyte and 4 thrombocyte transfu-
sions; in the group without asparaginase, the maximum
was 1 for both erythrocyte- and thrombocyte transfusions.
In addition, the occurrence of grade 3–4 leukopenia and
neutropenia was higher in the group of patients with
concomitant asparaginase treatment (leukopenia 59% vs.
31%, and neutropenia 86% vs. 63%, respectively).
However, the number of infections during the high dose
MTX courses did not differ between patients with or with-
out concomitant asparaginase treatment.
Table 2. Patient characteristics.
No asparaginase during
high dose MTX courses
n¼ 50
Asparaginase during
high doses MTX courses
n¼ 23 p Value
Sex (%) – – .621
Male 27 (54%) 14 (61%) –
Female 23 (46%) 9 (39%) –
Age at diagnoses, years,
median (IQR)
5.4 (3.0–9.2) 4.1 (3.4–5.5) .319
Type of ALL (%) – – .390
Pre-B cell ALL 12 (24%) 9 (39%) –
Common B-cell ALL 31 (62%) 10 (44%) –
Pro-B cell ALL 1 (2%) 4 (17%) –
T-cell ALL 6 (12%) 0 (0%) –
Risk group (%) – – –
Standard risk 17 (34%) – –
Medium risk, discontinuous group 33 (66%) – –
Medium risk, continuous group – 23 (100%)a
IVIG therapy during protocol M (%) – – .762
Yes 11 (22%) 4 (17%) –
No 39 (78%) 19 (83%) –
Average troughb asparaginase level
during protocol M, IU/L,
mean (SD)
– 249 (48) –
MTX: methotrexate; IQR: interquartile range; ALL: acute lymphoblastic leukemia; IVIG: intravenous immunoglobulins; SD: standard deviation; MRD: min-
imal residual disease.
aOne patient had to switch to high risk therapy due to high minimal residual disease.
bTrough asparaginase level: 14 ± 2 days after an asparaginase dose.
Table 3. Toxicity during protocol M.
No asparaginase during
high dose MTX courses
n¼ 50
Asparaginase during
high doses MTX courses
n¼ 22a p Value
Number of infections, median (IQR) 0 (0–1) 0 (0–1) .347
Number of transfusions during
protocol M, median (IQR)
Erythrocytes 0 (0–0) 1 (0.75–2) <.001
Thrombocytes 0 (0–0) 0 (0–0.25) .033
Maximal grade 1–2
n (%)
Maximal grade 3–4
n (%)
Maximal grade 1–2
n (%)
Maximal grade 3–4
n (%)
Leukopenia 33 (66%)d 15 (30%)d 9 (41%)d 13 (59%)d .022
Neutropenia 12 (24%) 31 (62%)d 3 (14%) 19 (86%)d .032
Increased ALT/AST 16 (32%)d 1 (2%) 20 (91%)d 2 (9%) <.001
Increased creatinine prior to MTX 4 (8%) 0 1 (5%) 0 .504
Increased creatinine 48 h after MTX 2 (4%) 0 3 (14%) 0 .163
Decreased albumine 0d 0 14 (100%)c,d 0 <.001
Neurotoxicityb 5 (10%) 2 (4%) 6 (27%) 0 .233
Mucositis 18 (36%) 16 (32%) 10 (46%) 5 (23%) .580
Diarrhea 10 (20%) 1 (2%) 5 (23%) 1 (5%) .572
MTX: methotrexate; IQR: interquartile range; ALT: alanine transaminase; AST: aspartate transaminase.
aIn one patient, protocol M was not completed because he had to switch high risk therapy due to high minimal residual disease.
bNeurotoxicity included somnolence (grade 1–2), depressed consciousness (grade 1–2), agitation (grade 3–4), and seizures (grade 3–4).
cAlbumine was standardly measured only in part of the patients (n¼ 14 and n¼ 36 for the groups without and with asparaginase, respectively).
dStatistically significant (p< .05) after post-hoc analysis.
Grading according to the common terminology criteria for adverse events version 4.03.
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Regarding hepatotoxicity, significantly more
patients who were treated with asparaginase during
the high dose MTX courses had grade 1–2 increased
ALT and AST. On the other hand, grade 3–4 increased
ALT and AST only occurred in one and two patients of
the patients without and with concomitant asparagi-
nase treatment, respectively.
All patients with asparaginase had grade 1–2 hypo-
albuminemia, in contrast to patients without asparagi-
nase, who all had normal albumin levels. This,
however, had no clinical consequences.
The number of patients with increased creatinine,
neurotoxicity, mucositis, and diarrhea did not signifi-
cantly differ between the groups. Nephrotoxicity 48 h
after one of the high dose MTX courses occurred in 5
patients (3 patients with and 2 patients without aspar-
aginase), all grade 1–2.
The duration of protocol M, and prolonged and
extra hospital admissions during this treatment phase
are described in Table 4. Without any delay, protocol
M would have a duration of 63 days. The mean dur-
ation of protocol M for patients without asparaginase
administrations was 68 days (SD: 7 days); the mean
duration for patients with asparaginase administra-
tions was 80 days (SD: 14 days) (p¼ .001).
The hospital admission duration for MTX adminis-
tration is usually 2 days, although, among other clin-
ical reasons, admissions may be prolonged if plasma
48 h MTX plasma levels are >0.4 lM. There was no
statistically significant difference in the hospital admis-
sion duration between the groups. Also, there was no
statistically significant difference in the number of
extra hospital admissions (median number and IQR of
1 (0–1) for both groups).
MTX polyglutamates
In total, 240 erythrocyte MTXPG samples were
obtained. Longitudinally analyzed, MTXPG 2–5 were
lower in patients treated with asparaginase during the
high dose MTX courses. All MTXPG levels increased in
the consecutive high dose MTX courses (Figure 1). The
number of days between the MTX dose and sampling,
sex, and age did not significantly alter the MTXPG lev-
els. Also, the timing of the asparaginase dose with
respect to the MTX dose did not have a significant
influence on the MTXPGs. Figure 1 shows the median
MTXPG levels two weeks (12–16 days) after the high
dose MTX courses, corrected for the administration of
erythrocyte transfusions. Comparing patients with and
without concomitant asparaginase treatment, the
median (IQR) MTXPG levels were 4.0 lM (2.1–7.6 lM)
vs. 10.8 lM (6.6–19.8lM) for MTXPG 2 (p< .001),
18.7 lM (9.9–27.2lM) vs. 27.5 lM (18.5–37.4lM) for
MTXPG 3 (p¼ .004), 29.2lM (13.0–42.1lM) vs. 37.9lM
(26.6–58.3 lM) for MTXPG 4 (p¼ .002), and 19.4lM
(9.9–28.8lM) versus 32.8lM (20.3–48.1 lM) for MTXPG
5 (p¼ .004). Overall, the median (IQR) MTXPG 2–5 lev-
els were 72.7lM (37.7–110.4 lM) for patients with and
118.6 lM (74.8–16.1lM) for patients without asparagi-
nase treatment during protocol M (p<.001).
MTX plasma levels
The 48 h MTX plasma levels are shown in Table 4 and
shown in Figure 2. The median 48 h MTX plasma level
for patients without concomitant asparaginase treat-
ment was 0.39lM (IQR: 0.30–0.52lM); for patients
with concomitant asparaginase treatment, this was
0.39 lM (IQR: 0.26–0.64lM). In the longitudinal ana-
lysis, we have corrected for sex, age, and albumin.
Creatinine levels were not increased just prior to the
MTX doses. During the analysis, outliers violated the
normality assumption, even after log-transformation of
the data. Therefore, we have performed the analysis
also excluding the extreme outliers (n¼ 5). In both
models, concomitant asparaginase treatment did not
statistically significantly alter the 48 h plasma levels
Table 4. Duration of protocol M.
No asparaginase during
high dose MTX courses
n¼ 49a
Asparaginase during
high doses MTX courses
n¼ 22a p Value
Duration of protocol M in days, mean ± SD 68 ± 7 80 ± 14 .001
Duration of hospital admissions for MTX administration in days, median (IQR) – – –
Dose 1 2 (2–4) 2 (2–2) .087
Dose 2 2 (2–3) 2 (2–3) .610
Dose 3 2 (2–3) 2 (2–2) .407
Dose 4 2 (2–4) 2 (2–3) .099
Extra hospital admissions during protocol M (median, IQR) 0 (0–1) 0 (0–1) .266
T48 MTX plasma level, lM (median, IQR) 0.39 (0.30–0.52) 0.39 (0.26–0.64) .510b
MTX: methotrexate; SD: standard deviation; IQR: interquartile range.
aIn two patients, protocol M was not completed. In one patient due to severe neurotoxicity, protocol M was postponed for several weeks; the other
patient had to switch to high risk treatment during protocol M.
bThe difference in T48 MTX plasma levels between the groups was analyzed using marginal models and corrected for sex, age and albumin levels.
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Figure 1. Erythrocyte MTXPG concentrations. This figure shows the concentrations of erythrocyte MTXPG 2, 3, 4, 5, and 2–5,
measured two weeks (12–16 days) after the MTX dose, excluding measurements less than two weeks after an erythrocyte transfu-
sion. The p values have been obtained from the longitudinal analysis. The MTXPG 2–5 levels are shown per MTX dose. The box-
plot includes the 25th, 50th, and 75th percentile in the boxes, the outliers (), extreme outliers (), and the ranges (indicated by
the whiskers).
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(p¼ .624 with outliers and p¼ .510 without outliers).
Also, the albumin levels did not significantly affect the
48 h MTX plasma levels.
Discussion
In this study, the toxicity and efficacy of high dose
MTX were analyzed for patients with and without con-
comitant asparaginase therapy. Patients with asparagi-
nase treatment had more often severe neutropenia
and leukopenia, and they received more erythrocyte
and thrombocyte transfusions. However, the most
important consequence of myelosuppression, namely
the occurrence of (severe) infections, did not differ
between the groups. As a result of this myelosuppres-
sion, the high dose MTX courses had to be postponed
more often in patients with asparaginase, resulting in
a delay of protocol M. It could be questioned if this
delay is clinically relevant. It could even have a posi-
tive effect as MTX therapy may be more effective
when administered every three weeks instead of two:
a possible rescue effect of folinic acid on leukemic
cells may be diminished three weeks after the previ-
ous dose [26,27]. In addition to a difference in myelo-
suppression, all patients in the group with
asparaginase had increased ALT and AST, although
the far majority had grade 1–2 hepatotoxicity which
had no clinical consequences.
Beside differences in myelosuppression and hepato-
toxicity, we have found lower albumin levels in
patients who were treated with asparaginase. MTX is a
week acid and binds to serum albumin. Reiss et al.
have shown that hypoalbuminemia is associated with
decreased MTX clearance and an increased length of
hospitalization [28]. In our patients, however, the 48 h
MTX plasma levels and length of hospitalization did
not differ in the patients with and without hypoalbu-
minemia. Unfortunately, in the study of Reiss et al.,
the severity of hypoalbuminemia was not reported. In
our study, patients only had mild (grade 1–2) hypoal-
buminemia, possibly explaining the lack of association
between albumin levels, and MTX clearance, and
hospitalization.
The occurrence of nephrotoxicity, neurotoxicity, and
mucositis did not differ between the groups. The inci-
dence of these side effects was in line with the inci-
dences found by den Hoed et al., who have shown
CTCAE grade 3–4 neurotoxicity in 3% and CTCAE
grade 3–4 mucositis in 20% of the patients treated
with high dose MTX [27]. The occurrence of nephro-
toxicity has been reported in 2–10% of the patients
after high dose MTX courses [29]. These toxicities have
been correlated with MTX plasma levels [27,29]. In our
study, asparaginase has no effect on these plasma lev-
els, which may explain that the toxicity did not differ
between the groups.
Beside toxicity during the high dose MTX courses,
one should consider the toxicity during the intensifica-
tion phase as well: patients in the continuous asparagi-
nase dosing schedule will receive fewer asparaginase
doses during the intensification and maintenance
phase. These patients, probably, will tolerate a higher
amount of 6-mercaptopurine and MTX, which is admin-
istered during these phases when they have completed
their asparaginase doses, as reported by Merryman
et al. [30] In addition, one could expect fewer infections
and less hepatotoxicity during the intensification and
maintenance phase in these patients.
Regarding MTX efficacy, we found that erythrocyte
MTXPG levels were significantly lower in patients who
were treated with asparaginase during the high dose
MTX courses. The question is whether this is of clinical
relevance. To the best of our knowledge, this is the
first study comparing MTXPG levels in patients treated
with and without asparaginase during high dose MTX.
In earlier studies, Jolivet et al. and Sur et al. have con-
cluded that asparaginase inhibits MTX polyglutamina-
tion in vitro by inhibition of FPGS due to asparagine
Figure 2. MTX plasma levels. This figure shows the 48 h MTX
plasma levels after each high dose MTX for patients with and
without concomitant asparaginase treatment. The p value has
been obtained from the longitudinal analysis. The boxplot
includes the 25th, 50th, and 75th percentile in the boxes, the
outliers (), and the ranges (indicated by the whiskers). The
extreme outliers were excluded as described. The T48 MTX
plasma levels did not differ between the patients who were
treated with and without asparaginase (p¼.510).
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depletion [11,12]. However, this resulted in a decrease
of mainly long chain MTXPG levels: MTXPG 4 levels
were more than 80% lower, MTXPG 5 was not even
measurable, but MTXPG 2 did not alter with asparagi-
nase treatment. In our study, all MTXPG chains were
lower, regardless of the chain length and, in contrast
to the in vitro studies, all long chain MTXPGs were
formed. Moreover, the overall decrease in levels is not
as large as was found in vitro by Jolivet et al. This
implies that the effect of asparaginase on MTX efficacy
in vivo is smaller. However, it also has to be taken into
account that erythroblasts, in which the erythrocyte
MTX polyglutamination takes place, contain aspara-
gine synthetase [31] and therefore, in contrast to leu-
kemic blasts, do not depend on extracellular
asparagine levels. This may influence the effect of
asparaginase on MTX polyglutamination. In addition,
the type and cytogenetic characteristics of the leu-
kemic cells influence the degree of MTX polyglutami-
nation. For example, the formation of MTXPGs is
increased in hyperdiploid ALL and decreased in T-cell
ALL [32,33]. On the other hand, also the asparaginase
sensitivity varies, and leukemic cells which are less
sensitive for asparaginase may encounter a smaller
effect of asparagine depletion on MTX polyglutamina-
tion [34]. When the DCOG ALL-11 has been com-
pleted, survival analyses might provide differences
between the asparaginase treatment arms, which then
may be explained by the difference in MTXPG levels
found in this study, although the number of relapses
may be too low to draw these conclusions.
Though we found inhibition of MTX polyglutamyla-
tion, there was no effect of the timing of asparaginase
administration on the MTXPG levels. In our study,
asparaginase was either administrated directly or a
week after the MTX. Several in vitro studies have
shown that asparaginase inhibits MTX polyglutamyla-
tion and efficacy specifically when asparaginase has
been administered prior to the MTX. Vice versa, aspar-
aginase administration after MTX would have a syner-
gistic effect [10–12,17]. In line with these findings,
several treatment protocols prove to be successful
when asparaginase is administered after MTX
[2,6,35,36]. These protocols, however, used native
E. coli asparaginase, which has shorter therapeutic
activity than PEGasparaginase (three days versus two
weeks). By administering PEGasparaginase biweekly,
asparagine is continually depleted, which could
explain our finding that the timing of asparaginase
administration relative to the MTX doses had no effect
on the formation of MTXPGs. However, in our study,
patients were not treated with asparaginase directly
prior to MTX. Therefore, we cannot draw conclusions
about a possible effect of very high (top) asparaginase
activity levels prior to MTX administration.
We conclude that the schedule-related antagonism
seen in the early in vitro studies seems less important
in vivo, especially when patients are treated with
PEGasparaginase during the high dose MTX. In add-
ition, the results of this study suggest that MTX tox-
icity caused by concomitant asparaginase therapy only
slightly increases, and would be acceptable.
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